Eisai
Eisai, established in 1941, is a global human healthcare company headquartered in Japan. It operates as an integrated pharmaceutical business, focusing on two core therapeutic areas: oncology and neurology, including dementia-related and neurodegenerative diseases. Eisai's business spans multiple regions, with significant operations in Japan, the Americas, China, Asia, and Europe, Middle East, and Africa. The company's portfolio comprises prescription medicines for various indications, including central nervous system disorders, metastatic breast cancer, and diabetes. Eisai India, a 100% subsidiary, was the first Japanese company to enter the Indian pharmaceutical market, offering a range of products and maintaining a dedicated field force. Eisai's manufacturing and research complex in Vizag, India, produces drug substances, drug products, and conducts developmental research, with certifications from regulatory bodies such as USFDA, PMDA, MHRA, and WHO. Eisai Inc., its U.S. subsidiary, is committed to addressing unmet healthcare needs and fostering strong alliances. Eisai Innovation, a strategic investment organization, seeks synergies between the scientific community and Eisai's network.
27 past transactions
Egenesis
Series D in 2024
Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.
Seed Therapeutics
Series A in 2024
Seed Therapeutics is a biotechnology company focused on developing targeted protein degradation therapeutics by harnessing and engineering molecules, including molecular glues, to attack protein targets implicated in cancer and neurodegenerative diseases. The company concentrates on research and development to create novel drug candidates for previously undruggable diseases.
RecoMed
Corporate Round in 2024
RecoMed is South Africa’s largest and rapidly growing online healthcare booking platform, designed to efficiently connect patients with healthcare providers. Its core offering is a mobile-friendly booking portal that allows users to easily find and schedule appointments with various practitioners, eliminating the need for phone calls and paperwork. Additionally, RecoMed has created customized, white-labelled solutions for prominent healthcare entities, enhancing the accessibility and convenience of healthcare services. By operating as a robust platform that serves both consumers and B2B clients, RecoMed facilitates real-time connections between doctors and patients while also supporting professionals in expanding their practices and improving patient experiences within the broader healthcare, life insurance, and corporate wellness sectors.
C2N Diagnostics
Corporate Round in 2024
C2N Diagnostics, LLC is a privately held company focused on the development of protein diagnostics and therapeutics targeting progressive neurodegeneration, particularly Alzheimer's disease. Founded in 2007 by Drs. David Holtzman and Randall Bateman from Washington University School of Medicine, along with LifeTech Research, the company operates from the Center for Emerging Technologies in St. Louis. C2N Diagnostics specializes in mass spectrometry-based techniques that allow for the precise identification, quantification, and monitoring of proteins and biomolecules associated with neurological disorders. By providing accurate and sensitive diagnostics, the company aims to enhance the detection and characterization of neurocognitive disorders, ultimately supporting improved patient care and treatment strategies.
Hyku
Seed Round in 2023
Hyku is a biotechnology company focused on developing small molecule therapeutics that utilize precise covalent targeting to address disease-causing proteins. The company employs a unique platform to identify molecules that covalently bind to non-cysteine amino acids, facilitating the creation of innovative medicines. Hyku's approach aims to tackle significant challenges in the treatment of various diseases, including issues related to selectivity, druggability, and resistance. By advancing the science of covalent medicines, Hyku strives to enhance treatment options and improve patient outcomes.
Casma Therapeutics
Series C in 2022
Casma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing innovative therapeutic strategies centered on the natural cellular process of autophagy. Founded in 2017, the company aims to enhance autophagy to improve the clearance of unwanted proteins, organelles, and pathogens, thereby addressing significant medical challenges. Casma Therapeutics is advancing preclinical programs targeting various conditions, including muscle disorders, liver disease, inflammatory disorders, and neurodegenerative diseases. By harnessing and manipulating the autophagy system, the company seeks to arrest or reverse disease progression, ultimately enabling physicians to meet unmet medical needs and provide effective treatments for patients with serious health issues.
Lifenet Insurance
Post in 2022
Lifenet Insurance Company is a life insurance provider based in Tokyo, Japan, established in 2006. The company specializes in underwriting a variety of insurance products, including term death, whole life, medical, cancer, and disability insurance. Lifenet also offers health counseling services, catering to the diverse needs of its clientele. Notably, the company sells its products directly to consumers through the Internet, enhancing accessibility and customer engagement.
Tacit Therapeutics
Venture Round in 2022
Tacit Therapeutics is a biotechnology company focused on developing RNA-targeting treatments aimed at repairing mutated genes associated with devastating diseases. Founded in 2021 and located in South San Francisco, California, the company utilizes pre-existing components of human cells to create innovative and non-immunogenic approaches for gene modification. By offering a broadly applicable solution, Tacit Therapeutics enables biotechnology professionals to pursue effective treatments for genetic disorders that were previously deemed untreatable, thereby advancing the field of gene therapy.
Arteryex
Acquisition in 2022
Arteryex is a company focused on the development of systems and applications within the medical and healthcare sectors. It specializes in the commissioned development of tailored solutions and operates its own applications, including Pashatto Karte and the LEAF app, which supports health management for employees. Additionally, Arteryex has created an enterprise data management platform designed to optimize health management and medical care. This platform utilizes advanced technologies such as blockchain and artificial intelligence to enhance the retrieval and sharing of medical documents. By maximizing data utilization, Arteryex provides access to personal health record-related services for patients, healthcare professionals, and the broader community.
Ractigen Therapeutics
Series A in 2022
Ractigen Therapeutics is an early-stage pharmaceutical company dedicated to developing first-in-class therapies that selectively restore the expression of therapeutic genes silenced in diseased cells. Founded in 2016 by pioneers in the RNA activation field, the company leverages a groundbreaking discovery from the University of California San Francisco, known as RNA activation (RNAa). Ractigen's innovative approach aims to address diseases stemming from inadequate gene expression, with a focus on central nervous system disorders, tumors, liver diseases, and ophthalmic conditions. The company is building a promising pipeline of candidate medicines to meet significant unmet medical needs.
Prism BioLab
Series C in 2021
Prism BioLab is focused on drug discovery and development, utilizing its proprietary PepMetics Technology to create therapeutic agents. The company specializes in treatments for non-oncology indications, particularly targeting conditions such as pulmonary fibrosis and other incurable diseases. By leveraging its innovative platform, Prism BioLab aims to provide effective solutions for these challenging health issues.
Neuroglee Health
Series A in 2021
Neuroglee Health is a digital therapeutic platform focused on addressing the needs of patients in the early stages of neurodegenerative diseases. The company develops innovative therapeutic devices that offer treatment and monitoring tools aimed at preserving cognitive function and promoting patient independence. By utilizing cognitive and neurobehavioral mechanisms, Neuroglee Health engages users on an individual basis, enabling them to take an active role in their treatment. The platform also provides consistent insights into the efficacy of therapies, which can facilitate accelerated drug development. Through its comprehensive approach, Neuroglee Health aims to empower patients and improve their quality of life while navigating the challenges posed by neurodegenerative conditions.
Sola Biosciences
Seed Round in 2021
Sola Biosciences is a biotechnology company focused on developing transformative gene therapies for conformational diseases like Amyotrophic Lateral Sclerosis (ALS) and Huntington's disease (HD). The company employs its proprietary chaperone platform technology to selectively reduce abnormal proteins that cause toxic clumps in neurons, aiming to provide permanent treatment solutions. Additionally, Sola Biosciences has developed a modular bioreactor called 'Sola', enabling users to grow cells efficiently.
Altoida
Venture Round in 2021
Altoida AG, founded in 2016 and headquartered in Lucerne, Switzerland, specializes in developing innovative healthcare solutions for Alzheimer's patients. The company has created a platform that transforms the assessment of brain function and the diagnosis of neurological diseases through the use of smartphones and tablets. Their flagship product, a Computerized Cognitive Assessment Aid, has received FDA Breakthrough Device Designation, reflecting its potential to significantly improve patient outcomes. Altoida's approach is grounded in over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence, employing machine-learning algorithms to evaluate cognitive and functional performance. The platform aims to enable healthcare professionals to detect Alzheimer's and dementia at an early stage, providing critical insights that can inform treatment strategies.
Voluntis
Post in 2021
Voluntis, established in 2001, specializes in developing digital therapeutic solutions for diabetes, oncology, and other therapeutic areas. The company offers products such as Insulia, Diabeo, Oleena, and AstraZeneca, which provide automated insulin dose recommendations, patient-specific dosage suggestions, and management of side effects like hypertension and diarrhea. Voluntis collaborates with pharmaceutical companies like Bristol-Myers Squibb to co-develop digital therapeutics for oncology. With a patient-centric approach, Voluntis aims to enhance medical practices and improve healthcare system efficiency through secure, collaborative, and innovative digital health solutions.
Allm
Series A in 2021
Allm Inc. is a Tokyo-based medical ICT company that specializes in developing advanced medical communication platforms aimed at enhancing healthcare delivery. Founded in 2001 and formerly known as SkillUpJapan Corp., Allm offers a suite of applications designed to facilitate communication among healthcare professionals. Key products include Kaigo and Kango, which support home care workers and nurses respectively; MySOS, a first-aid support application; AcaMed, an academic platform for medical research; and FollowUP, a business intelligence tool for real-time management information. Allm's solutions are deployed in over 18 countries, including the United States, Japan, and various regions in Europe, South America, the Middle East, and Africa. The company's innovations aim to improve the efficiency of healthcare services, enhance information sharing, and ultimately contribute to better community care systems.
Neuroglee Health
Pre Seed Round in 2020
Neuroglee Health is a digital therapeutic platform focused on addressing the needs of patients in the early stages of neurodegenerative diseases. The company develops innovative therapeutic devices that offer treatment and monitoring tools aimed at preserving cognitive function and promoting patient independence. By utilizing cognitive and neurobehavioral mechanisms, Neuroglee Health engages users on an individual basis, enabling them to take an active role in their treatment. The platform also provides consistent insights into the efficacy of therapies, which can facilitate accelerated drug development. Through its comprehensive approach, Neuroglee Health aims to empower patients and improve their quality of life while navigating the challenges posed by neurodegenerative conditions.
Unlearn.AI
Series A in 2020
Unlearn.AI, Inc. is a biotechnology company based in San Francisco, California, that specializes in developing innovative software tools for clinical research. Established in 2017, Unlearn.AI focuses on enhancing clinical trials through its unique digital twin technology, known as TwinRCT. This approach utilizes machine learning to create prognostic digital twins for individual patients, allowing for more accurate estimations of treatment effects while reducing the number of participants needed. The company also offers services for Clinical Trial Design, which helps determine inclusion criteria, endpoints, and study sizes, as well as Synthetic Control Arms that can minimize or eliminate the need for concurrent control groups. Additionally, Unlearn.AI provides Subgroup Analysis to identify and analyze specific patient subgroups within trial results. By integrating expertise from pharmaceuticals, medical technology, and machine learning, Unlearn.AI aims to transform clinical trials to improve outcomes for both patients and sponsors.
Darmiyan
Seed Round in 2020
Darmiyan, Inc. is a biotechnology company focused on early detection and monitoring of neurodegenerative diseases, including Alzheimer's disease. Founded in 2014 and based in San Francisco, California, the company has developed a proprietary diagnostic software platform known as BrainSee. This Software as a Service (SaaS) platform utilizes standard clinical brain MRI scans and basic cognitive tests to generate detailed brain maps and quantifications of neurodegeneration in each voxel. BrainSee provides a summary score reflecting an individual's brain health and the likelihood of future cognitive decline, allowing for diagnosis at early stages when treatment options are most effective. The technology, referred to as The Virtual Microscope, employs advanced medical image analysis and artificial intelligence, underpinned by over 40 years of neuroscience research. It has undergone successful third-party validation in the United States and Canada, demonstrating high accuracy and consistency in predicting mild cognitive impairment, and has received endorsements from notable figures in the medical community.
Caraway Therapeutics
Venture Round in 2020
Caraway Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing innovative treatments for neurodegenerative diseases by modulating mitophagy and autophagy. The company aims to address the degradation of toxic cellular components, which is a key factor in various neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis. By leveraging an understanding of critical neural pathways, Caraway Therapeutics seeks to discover and develop novel small molecules that can restore cellular balance and improve lysosomal function. Founded in 2018 and initially known as Rheostat Therapeutics, Inc., the company rebranded in 2019 to reflect its commitment to finding effective therapies for patients affected by these debilitating diseases.
Numab
Series B in 2019
Numab is a biotechnology company focused on developing antibody-based therapies for severe diseases like chronic inflammation and cancer. Its proprietary platform streamlines the discovery process by reducing randomness, predictably generating ready-to-develop multispecific biotherapeutics tailored to engage multiple targets simultaneously. This enables healthcare industries to access Numab's platform for innovative treatments in these areas.
Allm
Corporate Round in 2019
Allm Inc. is a Tokyo-based medical ICT company that specializes in developing advanced medical communication platforms aimed at enhancing healthcare delivery. Founded in 2001 and formerly known as SkillUpJapan Corp., Allm offers a suite of applications designed to facilitate communication among healthcare professionals. Key products include Kaigo and Kango, which support home care workers and nurses respectively; MySOS, a first-aid support application; AcaMed, an academic platform for medical research; and FollowUP, a business intelligence tool for real-time management information. Allm's solutions are deployed in over 18 countries, including the United States, Japan, and various regions in Europe, South America, the Middle East, and Africa. The company's innovations aim to improve the efficiency of healthcare services, enhance information sharing, and ultimately contribute to better community care systems.
iPS PORTAL
Venture Round in 2015
iPS PORTAL, Inc. is a Kyoto-based company established in 2014 that specializes in the development of instruments for analyzing and measuring cells, with a particular focus on induced pluripotent stem (iPS) cell technology. The company offers contract testing services for iPS cells, supporting researchers and healthcare companies in the practical application of this technology. Its services encompass research and development outsourcing, concept planning, and training programs in cell culture, all aimed at facilitating the advancement of drug discovery and regenerative medicine. By promoting the widespread use of iPS cell technology, iPS PORTAL plays a vital role in accelerating research and commercialization efforts within the healthcare sector.
AkaRx
Acquisition in 2010
AkaRx, Inc., a biopharmaceutical company, develops therapeutic treatments for unmet medical needs. Its product includes AKR-501, an orally-available small molecule for use in the treatment of thrombocytopenia. The company was founded in 2005 and is headquartered in Paramus, New Jersey.
SymBio Pharmaceuticals
Venture Round in 2009
SymBio Pharmaceuticals Limited is a biopharmaceutical company based in Tokyo, Japan, founded in 2005. It specializes in the research, development, manufacturing, and marketing of pharmaceutical drugs, primarily focusing on oncology and hematology. The company develops various anti-cancer agents, including Treakisym, an established treatment for non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia, which is currently undergoing Phase III clinical trials for relapsed/refractory diffuse large B-cell lymphoma. Additionally, SymBio is advancing several formulations, such as SyB L-1701—a ready-to-dilute formulation—and SyB L-1702, a rapid infusion formulation. Rigosertib, an oral preparation under development, is in Phase I clinical trials for solid tumors. SymBio is also working on SyB L-1101 and SyB C-1101 for higher-risk myelodysplastic syndromes, as well as SyB V-1901, an antiviral drug aimed at treating infectious diseases, and has operations across Japan, South Korea, China, Hong Kong, Taiwan, and Singapore.
MGI Pharma
Acquisition in 2008
MGI PHARMA, INC., a biopharmaceutical company, engages in the acquisition, research, development, and commercialization of pharmaceutical products for oncology and acute care applications. The company markets its products through sales organizations in the United States, as well as alliances with other pharmaceutical or biotechnology companies internationally. MGI PHARMA, INC. was founded in 1979 as Molecular Genetics, Inc. and changed its name to MGI PHARMA, INC. in 1990. The company is headquartered in Bloomington, Minnesota. It has facilities in Bloomington, Minnesota; Lexington, Massachusetts; and Baltimore, Maryland. As of January 25, 2008, MGI PHARMA, INC. operates as a subsidiary of Eisai Corporation of North America.
Morphotek
Acquisition in 2007
Morphotek, established in 2000, is a prominent life science company specializing in developing novel biological products to combat cancer, inflammation, and infectious diseases. The company's core technology, morphogenics, was co-invented by its current President and CEO, Dr. Nicholas Nicolaides, during his postgraduate research at Johns Hopkins Medical School. Morphotek focuses on discovering and developing monoclonal antibodies (mAbs) using this proprietary technology to treat various conditions such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. The company conducts independent research and clinical development programs for its drug candidates.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.